1. Momparler RL, Onetto-Pothier N: Drug resistance to cytosine arabinoside. In: Resistance to antineoplastic drugs, pp 353-367. D. Kessel, ed. CRC Press, Inc., 1989.
2. Braakhuis BJM, Van Dongen GAMS, Vermorken JB et al.: Preclinical in vivo activity of 2’,2’-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res. 51, 211–214, 1991.
3. Hertel LW, Broder GB, Kroin JS et al.: Evaluation of the antitumor activity of gemcitabine (2’,2’-difluoro-2’-deoxycytidine). Cancer Res. 50, 4417–4422, 1990.
4. Tanis B, Clavel M, Guastalla J et al.: Phase I study of gemcitabine (difluorodeoxycytidine; dFdC; LY 188011) administered in a two-weekly schedule. Proc. Am. Assoc. Cancer Res. 31, 207, 1990.
5. Grunewald R, Abbruzzese JL, Tarassoff P et al.: Saturation of 2’,2’-difluorodeoxycytidine 5’triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother. Pharmacol. 27, 258–262, 1991.